23 December 2019
EFPIA Japan

Thorsten Pöhl to become new chairman of EFPIA JapanTOKYO—23 December 2019— EFPIA Japan announced today that Thorsten Pöhl
(President and Representative Director, Boehringer Ingelheim Japan, Inc.) has been
appointed the new chairman of EFPIA Japan, effective 1 January 2020.
Heike Prinz (President and Representative Director, Bayer Yakuhin, Ltd.), who continues
in her current position as vice chairman, and Kazunari Tsunaba (President, Novartis
Pharma K.K.), who has been newly appointed vice chairman, will support Thorsten Pöhl in
his new role.
“I appreciate the trust that I have been given to lead EFPIA Japan in these challengingtimes,” says Thorsten Pöhl. “It is our foremost objective to bring innovative treatments andbreakthrough therapies to the Japanese patient. We will continue to work together with all
stakeholders to achieve this in all therapeutic areas as agilely as possible for theJapanese patients in need.”
EFPIA Japan Board Members as of 1 January 2020
ChairmanThorsten Pöhl (Nippon Boehringer Ingelheim Japan, Co.,
Ltd..)
Vice Chairmen Heike Prinz (Bayer Yakuhin, Ltd.)
Kazunari Tsunaba (Novartis Pharma K.K.),
Directors
Ole Mølskov Bech (Novo Nordisk Pharma Ltd.)
Stefan Woxström (AstraZeneca K.K.)
Paul Lirette (GlaxoSmithKline K.K.)
Takahiko Iwaya (Sanofi K.K.)
Alexandere De Muralt (Merck Biopharma Co., Ltd.)
Kanako Kikuchi (UCB Japan Co., Ltd.)
Director
Yoshitada Kimura (EFPIA Japan／Novo Nordisk Pharma
GeneralLtd.)

New

New

New
New

__________________________________________________________________EFPIA Japan Office
Marunouchi Kitaguchi Bldg., 6-5, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-8265
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

About EFPIA Japan:
Established in April 2002, EFPIA Japan represents 23 R&D-based European
pharmaceutical companies operating in Japan. In 2018, combined sales from the member
companies accounted for roughly 23% of the pharmaceutical market in Japan. The
mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through theearly introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen
dialogue with decision-makers in order to improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations):
EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents
the pharmaceutical industry operating in Europe. Through its direct membership of 36
national associations and 39 leading pharmaceutical companies, EFPIA provides thevoice of 1,900 companies committed to researching, developing and bringing newmedicines to improve health and quality of life around the world.
For more information please visit:
http://efpia.jp/ (EFPIA Japan)
http://www.efpia.eu (EFPIA)
Contact:
EFPIA Japan Office2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Phone: 03-6266-1354
Email: info@efpia.jp2

Thorsten Pöhl profile

Current position:
President and Representative Director of Boehringer Ingelheim Japan, Inc.
Chairman and Representative Director of the following companies:- Nippon Boehringer Ingelheim Co., Ltd.
- Boehringer Ingelheim Animal Health Japan Co., Ltd.
- Boehringer Ingelheim Seiyaku Co., Ltd.
Vice Chair of European Federation of Pharmaceutical Industries and Associations, Japan(EFPIA Japan).
Professional Experience
May 2016 President and Representative Director of Boehringer Ingelheim Japan, Inc.
Chairman and Representative Director of the following companies:- Nippon Boehringer Ingelheim Co., Ltd.
- SSP Co., Ltd. (until December 2016)- Boehringer Ingelheim Vetmedica Japan Co., Ltd.
- Boehringer Ingelheim Seiyaku Co., Ltd.
2013
President and CEO Boehringer Ingelheim España
2010
Senior Corporate Vice president, Talent Management, Boehringer Ingelheim GmbH2008
President and CEO Boehringer Ingelheim Mexico Promeco, S.A. de C.V.
2005
President and CEO Boehringer Ingelheim Norway KS
2001
President and CEO Boehringer Ingelheim del Ecuador Cia. Ltda.
1993
Joined Boehringer Ingelheim GmbH3